A Phase 1a Study of LOXO-435 in People with Advanced Solid Tumors Containing FGFR3 Gene Changes

Full Title

FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer with FGFR3 Alterations

Purpose

The purpose of this study is to find the highest dose of the investigational drug LOXO-435 that can be given safely in people with advanced solid tumors that have come back or continued to grow despite treatment and contain a change in the FGFR3 gene. LOXO-435 targets cells with this abnormality and blocks the activity of FGFR3, a protein that plays a role in cancer growth. Inhibiting this protein could slow or stop the growth of cancer. LOXO-435 is taken orally (by mouth).

Contact

For more information and to ask about eligibility for this study, please contact the office of Dr. Gopakumar Iyer at 646-888-4737.